nach oben

Erschienen in:

23.10.2014 | zertifizierte fortbildung

Mögliche Komplikationen bei der Nachsorge

Lungentransplantation

verfasst von: Dr. Urte Sommerwerck, T. Rabis, P. Fleimisch, H. Carstens, H. Teschler, M. Kamler

Erschienen in: Pneumo News | Ausgabe 1/2014

Einloggen, um Zugang zu erhalten

Zusammenfassung

Die Lungentransplantation (LuTX) ist eine Therapiemöglichkeit für Patienten mit terminalen Lungenerkrankungen. Primäres Organversagen, Infektionen, zelluläre und humorale Abstoßungsreaktionen, lymphozytische Bronchiolitis sowie die chronische Abstoßungsreaktion mit ihren Phänotypen Bronchiolitis-obliterans-Syndrom und restriktivem Allograft-Syndrom (RAS) sind inzwischen gut charakterisierte Komplikationen nach LuTX und Ursache für Erkrankungen und Mortalität.

Benden C, Edwards LB, Kucheryavaya AY et al (2013) The Registry of the International Society for Heart and Lung Transplantation: sixteenth official pediatric lung and heart-lung transplantation report — 2013; focus theme: age. J Heart Lung Transplant 32:989–997PubMedCrossRef

Christie JD, Edwards LB, Kucheryavaya AY et al (2012) The Registry of the International Society for Heart and Lung Transplantation: 29th adult lung and heart-lung transplant report — 2012. J Heart Lung Transplant 31:1073–1086PubMedCrossRef

Treede H, Glanville AR, Klepetko W et al (2012) Tacrolimus and cyclosporine have differential effects on the risk of development of bronchiolitis obliterans syndrome: results of a prospective, randomized international trial in lung transplantation. J Heart Lung Transplant 31:797–804PubMedCrossRef

Gullestad L, Mortensen SA, Eiskjaer H et al (2010) Two-year outcomes in thoracic transplant recipients after conversion to everolimus with reduced calcineurin inhibitor within a multicenter, open-label, randomized trial. Transplantation 90:1581–1589PubMedCrossRef

Bhorade S, Ahya VN, Baz MA et al (2011) Comparison of sirolimus with azathioprine in a tacrolimus-based immunosuppressive regimen in lung transplantation. Am J Respir Crit Care Med 183:379–387PubMedCrossRef

Euvrard S, Morelon E, Rostaing L et al (2012) Sirolimus and secondary skincancer prevention in kidney transplantation. N Engl J Med 367:329–339PubMedCrossRef

Hillen U, Griewank K, Sommerwerck U et al (2013) Tumor regression and sirolimus-based therapy in lung transplantation. J Heart Lung Transplant 32:938–939PubMedCrossRef

Christie JD, Edwards LB, Kucheryavaya AY et al (2011) The Registry of the International Society for Heart and Lung Transplantation: Twenty-eighth Adult Lung and Heart-Lung Transplant Report — 2011. J Heart Lung Transplant 30:1104–1122PubMedCrossRef

Jaksch P, Wiedemann D, Augustin V et al (2013) Antithymocyte globulin induction therapy improves survival in lung transplantation for cystic fibrosis. Transpl Int 26:34–41PubMedCrossRef

10.

Gupta D, Agarwal R, Aggarwal AN et al (2012) Guidelines for diagnosis and management of community- and hospital-acquired pneumonia in adults: joint ICS/NCCP(I) recommendations. Lung India 29:S27–S62PubMedCrossRefPubMedCentral

11.

Palmer SM, Limaye AP, Banks M et al (2010) Extended valganciclovir prophylaxis to prevent cytomegalovirus after lung transplantation: a randomized, controlled trial. Ann Intern Med 152:761–769PubMedCrossRef

12.

Schlischewsky E, Fuehner T, Warnecke G et al (2013) Clinical significance of quantitative cytomegalovirus detection in bronchoalveolar lavage fluid in lung transplant recipients. Transpl Infect Dis 15:60–69PubMedCrossRef

13.

Snydman DR, Limaye AP, Potena L, Zamora MR (2011) Update and review: state-of-the-art management of cytomegalovirus infection and disease following thoracic organ transplantation. Transplant Proc 43:S1–S17PubMedCrossRef

14.

Kotton CN, Kumar D, Caliendo AM et al (2010) International consensus guidelines on the management of cytomegalovirus in solid organ transplantation. Transplantation 89:779–795PubMedCrossRef

15.

Ruhnke M, Rickerts V, Cornely OA et al (2011) Diagnosis and therapy of Candida infections: joint recommendations of the German Speaking Mycological Society and the Paul-Ehrlich-Society for chemotherapy. Mycoses 54:279–310PubMedCrossRef

16.

Lewis RE, Viale P, Kontoyiannis DP (2012) The potential impact of antifungal drug resistance mechanisms on the host immune response to Candida. Virulence 3:368–376PubMedCrossRefPubMedCentral

17.

Kourkoumpetis TK, Desalermos A, Muhammed M, Mylonakis E (2012) Central nervous system aspergillosis: a series of 14 cases from a general hospital and review of 123 cases from the literature. Medicine (Baltimore) 91:328–336CrossRef

18.

Beirao F, Araujo R (2013) State of the art diagnostic of mold diseases: a practical guide for clinicians. Eur J Clin Microbiol Infect Dis 32:3–9PubMedCrossRef

19.

Porhownik NR (2013) Airway complications post lung transplantation. Curr Opin Pulm Med 19:174–180PubMedCrossRef

20.

Lischke R, Pozniak J, Vondrys D, Elliott MJ (2011) Novel biodegradable stents in the treatment of bronchial stenosis after lung transplantation. Eur J Cardiothorac Surg 40:619–624PubMed

21.

Gottlieb J, Fuehner T, Dierich M et al (2009) Are metallic stents really safe? A long-term analysis in lung transplant recipients. Eur Respir J 34:1417–1422PubMedCrossRef

22.

Sundset A, Lund MB, Hansen G et al (2012) Airway complications after lung transplantation: long-term outcome of silicone stenting. Respiration 83:245–252PubMedCrossRef

23.

Gordon IO, Bhorade S, Vigneswaran WT et al (2012) SaLUTaRy: survey of lung transplant rejection. J Heart Lung Transplant 31:972–979PubMedCrossRef

24.

Greenland JR, Jones KD, Hays SR et al (2013) Association of large-airway lymphocytic bronchitis with bronchiolitis obliterans syndrome. Am J Respir Crit Care Med 187:417–423PubMedCrossRefPubMedCentral

25.

Tait BD, Susal C, Gebel HM et al (2013) Consensus guidelines on the testing and clinical management issues associated with HLA and non-HLA antibodies in transplantation. Transplantation 95:19–47PubMedCrossRef

26.

Yabu JM, Higgins JP, Chen G et al (2011) C1q-fixing human leukocyte antigen antibodies are specific for predicting transplant glomerulopathy and late graft failure after kidney transplantation. Transplantation 91:342–347PubMedCrossRef

27.

Chin C, Chen G, Sequeria F et al (2011) Clinical usefulness of a novel C1q assay to detect immunoglobulin G antibodies capable of fixing complement in sensitized pediatric heart transplant patients. J Heart Lung Transplant 30:158–163PubMedCrossRef

28.

Berry G, Burke M, Andersen C et al (2013) Pathology of pulmonary antibody- mediated rejection: 2012 update from the Pathology Council of the ISHLT. J Heart Lung Transplant 32:14–21PubMedCrossRef

29.

Yousem SA, Zeevi A (2012) The histopathology of lung allograft dysfunction associated with the development of donor-specific HLA alloantibodies. Am J Surg Pathol 36:987–992PubMedCrossRef

30.

Hachem RR, Yusen RD, Meyers BF et al (2010) Anti-human leukocyte antigen antibodies and preemptive antibody-directed therapy after lung transplantation. J Heart Lung Transplant 29:973–980PubMedCrossRefPubMedCentral

31.

Lobo LJ, Aris RM, Schmitz J, Neuringer IP (2013) Donor-specific antibodies are associated with antibody-mediated rejection, acute cellular rejection, bronchiolitis obliterans syndrome, and cystic fibrosis after lung transplantation. J Heart Lung Transplant 32:70–77PubMedCrossRef

32.

Snyder LD, Wang Z, Chen DF et al (2013) Implications for human leukocyte antigen antibodies after lung transplantation: a 10-year experience in 441 patients. Chest 144:226–233PubMedCrossRefPubMedCentral

33.

Roberts DM, Jiang SH, Chadban SJ (2012) The treatment of acute antibody- mediated rejection in kidney transplant recipients — a systematic review. Transplantation 94:775–783PubMedCrossRef

34.

Lemy A, Toungouz M, Abramowicz D (2010) Bortezomib: a new player in pre- and post-transplant desensitization? Nephrol Dial Transplant 25:3480–3489PubMedCrossRef

35.

Woodle ES, Alloway RR, Girnita A (2011) Proteasome inhibitor treatment of antibody-mediated allograft rejection. Curr Opin Organ Transplant 16:434–438PubMedCrossRef

36.

Verleden GM, Vos R, Verleden SE et al (2011) Survival determinants in lung transplant patients with chronic allograft dysfunction. Transplantation 92:703–708PubMedCrossRef

37.

Vos R, Vanaudenaerde BM, Verleden SE et al (2011) A randomised controlled trial of azithromycin to prevent chronic rejection after lung transplantation. Eur Respir J 37:164–172PubMedCrossRef

38.

Finlen Copeland CA, Snyder LD, Zaas DW et al (2010) Survival after bronchiolitis obliterans syndrome among bilateral lung transplant recipients. Am J Respir Crit Care Med 182:784–789PubMedCrossRefPubMedCentral

39.

Weigt SS, DerHovanessian A, Wallace WD et al (2013) Bronchiolitis obliterans syndrome: the Achilles’ heel of lung transplantation. Semin Respir Crit Care Med 34:336–351PubMedCrossRef

40.

Jaksch P, Scheed A, Keplinger M et al (2012) A prospective interventional study on the use of extracorporeal photopheresis in patients with bronchiolitis obliterans syndrome after lung transplantation. J Heart Lung Transplant 31:950–957PubMedCrossRef

41.

Greer M, Dierich M, De Wall C et al (2013) Phenotyping established chronic lung allograft dysfunction predicts extracorporeal photopheresis response in lung transplant patients. Am J Transplant 13:911–918PubMedCrossRef

42.

Sato M, Waddell TK, Wagnetz U et al (2011) Restrictive allograft syndrome (RAS): a novel form of chronic lung allograft dysfunction. J Heart Lung Transplant 30:735–742PubMedCrossRef

43.

Kohno M, Perch M, Andersen E et al (2011) Treatment of intractable interstitial lung injury with alemtuzumab after lung transplantation. Transplant Proc 43:1868–1870PubMedCrossRef

44.

Vanaudenaerde BM, Meyts I, Vos R et al (2008) A dichotomy in bronchiolitis obliterans syndrome after lung transplantation revealed by azithromycin therapy. Eur Respir J 32:832–843PubMedCrossRef

45.

Verleden SE, Vandermeulen E, Ruttens D et al (2013) Neutrophilic reversible allograft dysfunction (NRAD) and restrictive allograft syndrome (RAS). Semin Respir Crit Care Med 34:352–360PubMedCrossRef

46.

Langer D, Burtin C, Schepers L et al (2012) Exercise training after lung transplantation improves participation in daily activity: a randomized controlled trial. Am J Transplant 12:1584–1592PubMedCrossRef

47.

DeNicola MM, Weigt SS, Belperio JA et al (2013) Pathologic findings in lung allografts with anti-HLA antibodies. J Heart Lung Transplant 32:326–332PubMedCrossRef

48.

Saini D, Weber J, Ramachandran S et al (2011) Alloimmunity-induced autoimmunity as a potential mechanism in the pathogenesis of chronic rejection of human lung allografts. J Heart Lung Transplant 30:624–631PubMedCrossRefPubMedCentral

49.

Tiriveedhi V, Angaswamy N, Brand D et al (2012) A shift in the collagen V antigenic epitope leads to T helper phenotype switch and immune response to self-antigen leading to chronic lung allograft rejection. Clin Exp Immunol 167:158–168PubMedCrossRefPubMedCentral

50.

Kastelijn EA, van Moorsel CH, Rijkers GT et al (2010) Polymorphisms in innate immunity genes associated with development of bronchiolitis obliterans after lung transplantation. J Heart Lung Transplant 29:665–671PubMedCrossRef

51.

Mertens V, Blondeau K, Van Oudenhove L et al (2011) Bile acids aspiration reduces survival in lung transplant recipients with BOS despite azithromycin. Am J Transplant 11:329–335PubMedCrossRef

52.

Paraskeva M, Bailey M, Levvey BJ et al (2011) Cytomegalovirus replication within the lung allograft is associated with bronchiolitis obliterans syndrome. Am J Transplant 11:2190–2196PubMedCrossRef

53.

Kumar D, Husain S, Chen MH et al (2010) A prospective molecular surveillance study evaluating the clinical impact of community-acquired respiratory viruses in lung transplant recipients. Transplantation 89:1028–1033PubMedCrossRef

54.

Gottlieb J, Schulz TF, Welte T et al (2009) Community-acquired respiratory viral infections in lung transplant recipients: a single season cohort study. Transplantation 87:1530–1537PubMedCrossRef

55.

Gottlieb J, Mattner F, Weissbrodt H et al (2009) Impact of graft colonization with gram-negative bacteria after lung transplantation on the development of bronchiolitis obliterans syndrome in recipients with cystic fibrosis. Respir Med 103:743–749PubMedCrossRef

56.

Weigt SS, Elashoff RM, Huang C et al (2009) Aspergillus colonization of the lung allograft is a risk factor for bronchiolitis obliterans syndrome. Am J Transplant 9:1903–1911PubMedCrossRef

Titel: Mögliche Komplikationen bei der Nachsorge
Lungentransplantation
verfasst von: Dr. Urte Sommerwerck
T. Rabis
P. Fleimisch
H. Carstens
H. Teschler
M. Kamler
Publikationsdatum: 23.10.2014
Verlag: Urban & Vogel
Erschienen in: Pneumo News / Ausgabe 1/2014
Print ISSN: 1865-5467
Elektronische ISSN: 2199-3866
DOI: https://doi.org/10.1007/s15033-014-0001-y

Leitlinien kompakt für die Innere Medizin

Mit medbee Pocketcards sicher entscheiden.

^{Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag}

Kostenlos registrieren

Neu im Fachgebiet Innere Medizin

25.04.2024 | Hypotonie | Nachrichten

Update Innere Medizin

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen

Springer Medizin

Mögliche Komplikationen bei der Nachsorge

Lungentransplantation

Zusammenfassung

Leitlinien kompakt für die Innere Medizin

Neu im Fachgebiet Innere Medizin

Niedriger diastolischer Blutdruck erhöht Risiko für schwere kardiovaskuläre Komplikationen

Therapiestart mit Blutdrucksenkern erhöht Frakturrisiko

Viel Bewegung in der Parkinsonforschung

Adjuvante Immuntherapie verlängert Leben bei RCC

Update Innere Medizin

Springer Medizin

Zusammenfassung

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 1/2014

Zwei neue Hoffnungen auf Progressionshemmung

Junge Raucher riskieren Asthma ihrer zukünftigen Kinder

Die Evidenzlage für den Einsatz inhalativer Antibiotika hat sich verbessert

Frühzeitige Kombitherapie bei PAH im Fokus

„Die Pneumologie ist darauf nicht vorbereitet“

Frühzeitige, zielorientierte Behandlung zahlt sich langfristig aus

Leitlinien kompakt für die Innere Medizin

Neu im Fachgebiet Innere Medizin

Niedriger diastolischer Blutdruck erhöht Risiko für schwere kardiovaskuläre Komplikationen

Therapiestart mit Blutdrucksenkern erhöht Frakturrisiko

Viel Bewegung in der Parkinsonforschung

Adjuvante Immuntherapie verlängert Leben bei RCC

Update Innere Medizin